Development of a new therapeutic agent for osteosarcoma using the natural organic compound decursin

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K09115
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Shirai Toshiharu 京都府立医科大学, 医学(系)研究科(研究院), 准教授 (20397186)
• Co-Investigator(Kenkyū-buntansha): 土田 真嗣 京都府立医科大学, 医学(系)研究科(研究院), 助教 (10719834) ; 寺内 竜 京都府立医科大学, 医学(系)研究科(研究院), 講師 (20575154)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: デカルシン / 骨肉腫 / シスプラチン / アポトーシス / 細胞周期 / 腎保護

Outline of Final Research Achievements

Osteosarcoma is a primary bone malignancies that predominates in children. No new therapeutic drug has been born for about 40 years, and the current treatment method administers a large amount of multiple anticancer drugs, resulting in serious side effects. This time, we examined the sensitizing effect of using decursin in combination with existing drugs, and examined whether side effects could be reduced.
Decursin acted on the cell cycle to suppress cell proliferation and induce apoptosis in a concentration and time-dependent manner. In experiments using mice, decursin suppressed the increase in tumor volume, and when used in combination with cisplatin, it showed a further antitumor effect. Cisplatin-induced renal dysfunction and renal epithelial cell damage were ameliorated by the combined use of decursin.

Free Research Field

骨・軟部腫瘍

Academic Significance and Societal Importance of the Research Achievements

したがって、デクリスンは骨肉腫細胞に対して抗腫瘍効果があり、シスプラチンと併用すると相乗効果があり、腎保護効果があります。 したがって、Decursin は骨肉腫の治療薬として有望です。